Результаты исследования EUROPA
Abstract
Дано описание рандомизированного многоцентрового двойного слепого плацебоконтролируемого исследования EUROPA (The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators), в котором изучалась способность иАПФ – периндоприла - уменьшать смертность от сердечно-сосудистых заболеваний, частоту ИМ и остановки сердца в широкой популяции больных со стабильной ИБС, не имеющих сердечной недостаточности или выраженной артериальной гипертонии.
About the Author
Ю. Белоусов
ГОУ ВПО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова», Москва
Russian Federation
Russian Federation
References
1. Murray C., Lopez A. The Global Burden of Disease. Cambridge: Harvard University Press, 1996.
2. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomized trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81–106.
3. The Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–89.
4. Lloyd.Jones D.M., Larson M.G., Beiser A. et al. Lifetime risk of developing coronary heart disease. Lancet 1999; 353: 89–92.
5. Flather M.D., Yusuf S., Kober L. et al. Long-term ACE-inhibitor therapy in patients with heart failure or left.ventricular dysfunction: a systematic overview of data from individual patients. Lancet 2000; 355: 1575–81.
6. Pfeffer M.A., Braunwald E., Moye L.A. et al for the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction and myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992; 327: 669–77.
7. The SOLVD Investigators. Effects of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685–91.
8. Acute Infarction Ramipril Efficacy (AIRE) Investigators. Effects of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821–28.
9. Kober L., Torp.Pedersen C., Carlsen J.E. et al for the Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin.converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 333: 1670–76.
10. Wing L., Reid C., Ryan P. et al for the Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin.converting.enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348: 583–92.
11. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high.risk patients. N Engl J Med 2000; 342: 145–53.
12. Yusuf S., Pepine C.J., Garces C. et al. Effects of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992; 340: 1173–78.
13. Rutherford J.D., Pfeffer M.A., Moye L.A. et al. Effects of captopril on ischemic events after myocardial infarction: results of the survival and ventricular enlargement trial. Circulation 1994; 90: 1731-38.
14. Dzau V.J., Bernstein K., Celermajer D., et al. Pathophysiology and therapeutic importance of tissue ACE: a consensus report. Cardiovasc Drugs Ther 2002; 16: 149–60.
15. Matsumoto K., Morishita R., Moriguchi A. et al. Inhibition of neointima by angiotensin-converting enzyme inhibitor in porcine coronary artery balloon.injury model. Hypertension 2001; 37: 270–74.
16. Hornig B., Kohler C., Drexler H. Role of bradykinin in mediating vascular effects of angiotensin.converting enzyme inhibitors in humans. Circulation 1997; 95: 1115–18.
17. Brown N.J., Agirbasli M.A., Williams G.H., Litchfield W.R., Vaughan D.E. Effect of activation and inhibition of the renin.angiotensin system on plasma PAI.1. Hypertension 1998; 32: 1225–32.
18. Candido R.A., Jandeleit.Dahm K., Cao Z., et al. Prevention of accelerated atherosclerosis by angiotensin.converting enzyme inhibition in diabetic apoliprotein E.deficient mice. Circulation 2000; 106: 246–53.
19. Dyker A.G., Grosset D.G., Lees K.R. Perindopril reduces blood pressure but not cerebral blood flow in patients with recent ischemic stroke. Stroke 1997; 28: 580–83.
20. Bartels G.L., Van den Heuvel AFM, Van Veldhuisen D.J., Van der Ent M., Remme W.J. Acute anti.ischemic effects of perindoprilat in men with coronary artery disease and their relation with left ventricular function. Am J Cardiol 1999; 83: 332–36.
21. Myers M.G. A dose.response study of perindopril in hypertension: effects of blood pressure 6 and 24 hours after dosing. Can J Cardiol 1996; 12: 1191–96.
22. Asmar R.G., Pannier B., Santoni J.P. et al. Reversion of cardiac hypertrophy and reduced arterial compliance after converting.enzyme inhibition in essential hypertension. Circulation 1988; 78: 941–50.
23. Thybo N.K., Korsgaard N., Eriksen S. et al. Dose.dependent effects of perindopril on blood pressure and small.artery structure. Hypertension 1994; 23: 659–66.
24. Gomma A.H., Fox K.M. on behalf of the EUROPA Investigators. The EUROPA trial: design, baseline demography and status of the substudies. Cardiovasc Drugs Ther 2001; 15: 169–79.
25. Myocardial infarction redefined: a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 2000; 21: 1502–13.
26. O’Brien P.C., Fleming T.R. A multiple testing procedure for clinical trials. Biometrics 1979; 35: 549–56.
27. Britten M.B., Zeiher A.M., Schachinger V. Clinical importance of coronary endothelial vasodilator dysfunction and therapeutic options. J Intern Med 1999; 245: 315–27.
28. Marui N., Offermann M.K., Swerlick R. et al. Vascular cell adhesion molecule.1 (VCAM.1) gene transcription and expression are regulated through an antioxidant.sensitive mechanism in human vascular endothelial cells. J Clin Invest 1993; 92: 1866–74.
29. Vaughan D.E., Lazos S.A., Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor.1 in cultured endothelial cells: a potential link between the renin.angiotensin system and thrombosis. J Clin Invest 1995; 95: 995–1001.
30. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high.risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid.Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–97.
31. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-788
32. Gomma AH and Fox KM on behalf of the EUROPA Investigators. The EUROPA trial: design, baseline demography and status of the substudies. Cardiovasc Drug Ther 2001;15:169-79.
Review
For citations:
. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2003;(4):35-43. (In Russ.)
Views:
3309
Email this article 